What happened with CHE today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Chemed Corporation owns two distinct service businesses, primarily in the United States. VITAS provides hospice and palliative care and contributes most of the company’s revenue. Roto-Rooter serves households and businesses that need plumbing repairs, drain cleaning and help with water damage.
VITAS cares for terminally ill patients, with routine home care generating most of its patient-care revenue. Medicare supplies the vast majority of its revenue, with Medicaid another source of government payment. Payments are mainly set amounts for each day of care, so profitability depends on managing care costs within those rates. Medicare limits payments to each hospice program and requires refunds above its overall cap. VITAS must also meet healthcare licensing, certification and care requirements to operate and receive payment.
Roto-Rooter earns mainly by completing service jobs for residential and commercial customers. Drain-cleaning calls can lead to excavation or water-restoration work; customers’ insurers cover part of most water-restoration jobs. Residential customers usually pay when work is finished, while commercial customers may receive short-term credit. Independent contractors and franchisees also operate under the Roto-Rooter name and pay fees.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
These peers shed light on VITAS, but Chemed also depends materially on plumbing and restoration demand at Roto-Rooter, which competes mainly with local and regional firms.
The Pennant Group, Inc. competes with Chemed’s VITAS for terminally ill patients and care referrals through its hospice and palliative services. Pennant receives payment from government programs, private-pay patients and residents, and managed care payors; its locally led hospice operations are the part to watch for competition over those patients.
Addus HomeCare Corp. competes with Chemed’s VITAS in caring for terminally ill patients, but also earns revenue from help with daily living and home nursing and therapy, paid for by government agencies, health plans, insurers and individuals. Its hospice results are the closer comparison for VITAS, rather than the whole home-care business.
BrightSpring Health Services, Inc. overlaps with Chemed’s VITAS through hospice and home-based primary care for patients covered by Medicare, Medicaid and commercial insurance. Watch those care services rather than its overall results: BrightSpring also earns revenue by dispensing medicines and providing pharmacy support, making it a broader business than VITAS.
Aveanna Healthcare Holdings Inc. competes with Chemed’s VITAS through its hospice agencies, but its much larger private-duty care business makes overall results a less direct comparison. Watch approvals to open or expand its hospice agencies: some states require permission before expansion, which can limit its competitive reach.
Chemed Corporation earningsThis company
Chemed's report will show whether more VITAS care days and Medicare payments are translating into profit, and whether Roto-Rooter's job volume can hold up against pressure on price and service mix.
Read VITAS care days alongside its segment margin: more care days with a steady margin would show that added care and Medicare payments are covering care costs; rising care days with a falling margin would mean costs or a shift in care mix are eating into the added revenue. Then compare Roto-Rooter's job volume with revenue per job: more jobs with stable revenue per job would show demand lifting sales, while more jobs offset by lower prices or a shift in service mix would mean revenue is not keeping pace. Together, these outcomes show whether Chemed's growth is reaching profit.
Fed Interest Rate Decision
For Chemed, the Fed’s rate decision signals whether interest on its floating-rate credit facility would cost more or less if the company borrows.
Expected4.0%Last release4.0%
If it comes in above expectations
If rates rise more than expected, interest on any borrowing through Chemed’s facility could increase, adding to its costs.
If it comes in below expectations
If rates fall more than expected, interest on any borrowing through Chemed’s facility could decrease, reducing its costs.
BrightSpring Health Services, Inc. earningsBTSG
BrightSpring Health Services, Inc.'s report offers a read on care demand around VITAS through its hospice and home-based primary-care services for patients covered by Medicare, Medicaid and commercial insurance.
Focus on BrightSpring's hospice and home-based primary-care services, not its medicine dispensing and pharmacy-support business. Stronger results in those care services would point to support for demand among patients covered by the same types of payors, a positive signal for VITAS's demand environment; weaker results would point the other way. BrightSpring is a broader business with a different service mix, so this is not a substitute for VITAS's own results. The takeaway is the direction of related care demand, not whether VITAS itself grew.
Addus HomeCare Corp. earningsADUS
Addus HomeCare Corp.'s hospice business competes with VITAS for terminally ill patients and referrals, so its hospice results offer a read on that competition.
Focus on Addus's hospice business, not its help with daily living, home nursing or therapy. Stronger hospice results would suggest this competitor is gaining ground in attracting patients or referrals, potentially increasing the pressure on VITAS to maintain its patient census; weaker results would ease that competitive signal. Addus's results alone cannot explain why patients choose one provider, but they can show whether the competitive setting for VITAS's patients and referrals is tightening or easing.
